(Q43715524)

26 November 2017

title

Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder (English)

1 reference

26 November 2017

Jacquetin B

1

1 reference

26 November 2017

Wyndaele J

series ordinal

2

1 reference

26 November 2017

language of work or name

1 reference

1 September 2001

1 reference

European Journal of Obstetrics Gynecology and Reproductive Biology

26 November 2017

published in

1 reference

26 November 2017

volume

98

1 reference

26 November 2017

issue

1

1 reference

26 November 2017

page(s)

97-102

1 reference

The patient with an overactive bladder--symptoms and quality-of-life issues

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

The overactive bladder: pharmacologic basis of drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Tolterodine--a new bladder-selective antimuscarinic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Dose-ranging study of tolterodine in patients with detrusor hyperreflexia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Placebo-the Drug of Choice in Female Motor Urge Incontinence?

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900561-3

7 January 2021

10.1016/S0301-2115(00)00561-3

Identifiers

DOI

1 reference

26 November 2017

1 reference